Gynécologie ASCORDIA01 ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses Paris, Saint-Cloud CAROLINE MALHAIRE, ROMAN ROUZIER
Sein CANTO (Paris) A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer. Paris PAUL-HENRI COTTU
Pédiatrie Tumeurs cérébrales CC-4047-BRN-001 A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS Paris FRANCOIS DOZ
Sein CirCA 01 - IC 2014-05 Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01). Paris JEAN-YVES PIERGA
Sein métastatique RH+ COMPLEEMENT-1 An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease. Paris, Saint-Cloud PAUL-HENRI COTTU, FLORENCE LEREBOURS
Pédiatrie Tumeurs solides CPZP034X2203 (VEG116731) A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors. Paris ISABELLE AERTS
Sein métastatique HER2+ HER2CLIMB (ONT-380-206) Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) Paris
Sein métastatique RH+ PADA-1 Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD
Sein RadioPARP A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease Paris
Sein métastatique RH+ SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer Paris, Saint-Cloud